Quantbot Technologies LP Invests $80,000 in Guardant Health, Inc. (NASDAQ:GH)

Quantbot Technologies LP acquired a new stake in Guardant Health, Inc. (NASDAQ:GH) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 2,614 shares of the company’s stock, valued at approximately $80,000.

A number of other large investors have also bought and sold shares of the business. R Squared Ltd acquired a new position in shares of Guardant Health during the fourth quarter worth about $26,000. SBI Securities Co. Ltd. bought a new position in Guardant Health in the fourth quarter valued at $43,000. Kimelman & Baird LLC acquired a new stake in Guardant Health in the 4th quarter valued at $58,000. Jones Financial Companies Lllp lifted its position in Guardant Health by 43.5% during the 4th quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company’s stock worth $82,000 after buying an additional 817 shares in the last quarter. Finally, Van ECK Associates Corp boosted its stake in shares of Guardant Health by 47.4% during the 4th quarter. Van ECK Associates Corp now owns 2,887 shares of the company’s stock worth $88,000 after buying an additional 929 shares during the last quarter. 92.60% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Canaccord Genuity Group lifted their target price on Guardant Health from $42.00 to $60.00 and gave the company a “buy” rating in a research report on Monday, February 24th. Piper Sandler increased their price objective on Guardant Health from $34.00 to $50.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Stephens restated an “overweight” rating and set a $55.00 target price on shares of Guardant Health in a report on Wednesday, March 26th. Barclays started coverage on shares of Guardant Health in a research note on Thursday, January 23rd. They issued an “overweight” rating and a $60.00 price target for the company. Finally, Scotiabank boosted their price objective on shares of Guardant Health from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a research note on Monday, February 24th. Twenty research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Guardant Health presently has a consensus rating of “Buy” and a consensus target price of $48.95.

Guardant Health Stock Performance

GH stock opened at $42.60 on Tuesday. Guardant Health, Inc. has a 52 week low of $15.81 and a 52 week high of $50.89. The company’s 50-day simple moving average is $44.78 and its 200 day simple moving average is $34.49. The company has a market capitalization of $5.26 billion, a PE ratio of -11.97 and a beta of 1.50.

Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The business had revenue of $201.81 million during the quarter, compared to analyst estimates of $192.50 million. On average, analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.